Hospital Formulary Status Yes (parenteral inj)
In-Hospital Cost will be updated
PharmaCare Formulary Status No
SA None
PharmaCare Coverage None
Outpatient Cost 250mg/ml inj - $91.69-105.91/vial (2ml)
Therapy of gram negative organisms resistant to gentamicin and tobramycin but susceptible to amikacin (HAP, UTI, other).
As combination therapy for the treatment of some Mycobacteria spp (i.e. M. abscessus).
Consult pharmacist for level interpretation and dose individualization.
HDEI dosing Target Trough <1 mg/L; Peak levels not recommended.
Conventional dosing Trough <5 mg/L. Target Peak 15-30 mg/L; peak levels usually not required but if drawn record time of dose and time of level draw as accurately as possible.
Monitor creatinine at least 3 times/week. Discontinue if any signs of ototoxicity.
Nephrotoxicity (IV)
Ototoxicity (IV)
Neuromuscular blockade (IV)
Increased nephrotoxicity: amphotericin B, cyclosporine, cisplatin, NSAIDS, contrast dye, vancomycin.
Increased ototoxicity: furosemide.
Increased risk of respiratory paralysis: neuromuscular blockade agents
Antimicrobial class: Aminoglycoside
Pregnancy category: D
Formal audiology assessment at baseline if planning to use aminoglycoside for >7d or if symptoms develop
Inform patient of risk of ototoxicity and to report any symptoms (oscillopsia, imbalance, hearing loss, tinnitus)
Average serum half life: 2.5 hr
Urine penetration: Therapeutic
Lung penetration: Therapeutic
CSF penetration: Poor
Biliary penetration: Moderate